COMP <GO>
ATR vs TMO // PIOTROSKI F-SCORE QUALITY
AptarGroup Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ATR 8
— TMO 5
▲ PIOTROSKI F-SCORE QUALITY LEADER: ATR
LAST: $137.20 (+5.02%) • MKT CAP: $8.31B
piotroski-score
9/9
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ATR VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ATR | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 41.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.90% | 9.30% | +2.60 | ATR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.3x | 30.4x | -18.10 | ATR | /valuation <GO> |
| Free Cash Flow Yield | 3.61% | 2.40% | +1.21 | ATR | /fcf-yield <GO> |
| Operating Margin | 13.30% | 17.40% | -4.10 | TMO | /operating-margins <GO> |
| Net Profit Margin | 10.40% | 15.10% | -4.70 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 5.40% | 3.90% | +1.50 | ATR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.45% | 0.24% | +1.21 | ATR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.88 | 4.50 | -0.62 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 9/9 | 8/9 | +1.00 | ATR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.70% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 77.4 | 59.1 | +18.22 | ATR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 0.94 | -0.01 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.6x | 36.3x | -16.70 | ATR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.31B | $262.22B | -$253.91B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ATR REV | TMO REV | ATR GROSS % | TMO GROSS % | ATR FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.78B | $44.56B | 44.0% | 44.0% | $299.6M | $6.29B |
| FY 2024 | $3.58B | $42.88B | 44.0% | 44.0% | $366.9M | $7.27B |
| FY 2023 | $3.49B | $42.86B | 44.0% | 44.0% | $418.3M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ATR // BETA 0.93
TMO // BETA 0.94